- September 27, 2022 05:58 PM AEST
- Team Kalkine Media
- September 27, 2022 02:02 PM AEST
- Sonal Goyal
Meet Dr Astrow – Chimeric’s (ASX:CHM) new VP of Translational Sciences
- September 09, 2022 01:10 AM AEST | Aditi Sarkar
Highlights,Chimeric welcomes Dr Stephanie H. Astrow as Vice President of Translational Sciences.,Dr Astrow has over two decades of experience in the fields of biotechnology and cell therapy.,She has extensive expertise in autologous as well as allogenic s...Read More...
Common and Practical Cryptocurrency Exchange Frameworks in 2022
- September 08, 2022 07:51 PM AEST | Harry Wilson (Guest)
Interested in cryptocurrency trading? We totally get it! The influence of online assets, which market participants can buy, store, or trade, has skyrocketed. With the emergence of novel business models and tech innovations, many individuals and industries...Read More...
How can EarlyBirds help map innovation possibilities for pink hydrogen?
- September 08, 2022 05:24 PM AEST | Mohammad Zaid
EarlyBirds platform can help various stakeholders in the hydrogen space to develop, find and implement suitable innovations.Read More...
IOUpay (ASX:IOU) jumps 13% on strategic partnership with IDSB targeting Malaysian civil servants
- September 08, 2022 04:34 PM AEST | Ankit Sethi
Highlights,IOUpay is strategically collaborating with IDSB to provide instalment-based consumer finance to Malaysia’s Federal Civil Servants.,The first project includes short-term bridging loans provided by IOUpay, which feed into 10-year term loans facil...Read More...
PhotosoftTM opens new avenues for Invion (ASX:IVX), shows antiviral activity against Zika virus
- September 08, 2022 02:51 PM AEST | Aditi Sarkar
Highlights,Invion has secured positive screening results from the in vitro study of Photosoft,TM,technology against the Zika virus.,Currently, there is no treatment available for the Zika virus, and its market is estimated to be worth $25bn and will grow ...Read More...
Imugene doses first patient with HER-Vaxx in nextHERIZON Phase 2 clinical trial
- September 08, 2022 02:45 PM AEST | Aditi Sarkar
Highlights,Imugene has completed dosing the first patient in the nextHERIZON Phase 2 clinical trial in HER-Vaxx, IMU’s cancer immunotherapy,The clinical trial is focused on studying HER-Vaxx in combination with chemotherapy or pembrolizumab in patients di...Read More...
Alchemy (ASX:ALY) hits new milestone, signs Native Title Agreements for WA projects
- September 08, 2022 01:41 PM AEST | Nitish Kumar
Highlights,Alchemy Resources has signed two Heritage Protection Agreements for its Karonie and Lake Rebecca projects.,The agreements will cover 17 exploration licences across the two Western Australian projects.,The agreements will enable Alchemy to build...Read More...
Prescient Therapeutics (ASX:PTX) teams up with prestigious cancer centre in the US
- September 08, 2022 01:37 PM AEST | Team Kalkine Media
Highlights,Prescient has entered into a strategic collaboration with MD Anderson, the biggest cancer centre in the US.,The collaboration, aimed at developing flexible CAR-T cell therapies, will combine Prescient's OmniCAR platform with an undisclosed, pro...Read More...